Nectar's ResPeg: Eli Lilly botched data analysis
The bull case for Nectar Therapeutics was that Eli Lilly's initial negative analysis of the ResPeg eczema drug was a misanalysis, and the corrected data showed a competitive efficacy delta in the low 20s.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.